Translating Modified Ashworth Scale into Functional Measures and Quantitative Kinematic Values: A Pilot Study by Frigge, Patrick
University of Wisconsin Milwaukee
UWM Digital Commons
Theses and Dissertations
August 2016
Translating Modified Ashworth Scale into
Functional Measures and Quantitative Kinematic
Values: A Pilot Study
Patrick Frigge
University of Wisconsin-Milwaukee
Follow this and additional works at: https://dc.uwm.edu/etd
Part of the Occupational Therapy Commons
This Thesis is brought to you for free and open access by UWM Digital Commons. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of UWM Digital Commons. For more information, please contact open-access@uwm.edu.
Recommended Citation
Frigge, Patrick, "Translating Modified Ashworth Scale into Functional Measures and Quantitative Kinematic Values: A Pilot Study"
(2016). Theses and Dissertations. 1264.
https://dc.uwm.edu/etd/1264
 TRANSLATING MODIFIED ASHWORTH SCALE INTO FUNCTIONAL MEASURES AND 
QUANTITATIVE KINEMATIC VALUES: A PILOT STUDY  
 
 
by 
 
 
Patrick D. Frigge 
 
 
 
 
 
 
 
 
 
 
A Thesis Submitted in 
 
Partial Fulfillment of the 
 
Requirements for the Degree of 
 
 
 
Master of Science 
 
in Occupational Therapy 
 
 
 
at 
 
The University of Wisconsin-Milwaukee 
 
August 2016 
 
 
 
ii 
ABSTRACT 
TRANSLATING MODIFIED ASHWORTH SCALE INTO FUNCTIONAL MEASURES AND 
QUANTITATIVE KINEMATIC VALUES: A PILOT STUDY  
by 
Patrick D. Frigge 
 
The University of Wisconsin-Milwaukee, 2016 
Under the Supervision of Professor Ying-Chih Wang, PhD 
 
 
Introduction: Spasticity is a motor disorder characterized by a velocity-dependent 
increase in tonic stretch reflexes. The gold standard for assessing spasticity in stroke patients is 
the Modified Ashworth Scale (MAS), but the scale is highly subjective to the clinician’s opinion 
and previous experience and lacks psychometric fidelity. Numerous studies have criticized the 
scale’s subjectivity and lack of rater reliability. Development of a quantitative spasticity device 
in routine clinical care is warranted. Before doing so, however, it is important to examine how 
MAS scores translate into functional measures and quantitative kinematic and/or kinetic values.  
Methods: Data from 20 subjects (6 female, 14 male; mean age 57 ± 10) with chronic 
hemiparesis secondary to a cerebrovascular accident (stroke) were used to examine the 
relationships between the MAS and residual impairments (active range of motion of shoulder 
flexion, elbow, and wrist, and muscle strength of the elbow flexion and extension), the MAS and 
functional limitations as measured by the Fugl-Meyer upper extremity assessment, finger to nose 
movement, the MAS and overall health status following stroke as measured by the Stroke Impact 
Scale, and to inspect whether there are potential kinematic values or physiological responses that 
can be used to identify the characteristics of the passive stretch (passive stretch duration, catch 
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angle, electromyography response). The data were collected at both the Rehabilitation Institute 
of Chicago and the University of Wisconsin-Milwaukee. 
 Results: Overall, results showed that stroke subjects who had more severe spasticity 
tended to have reduced range of motion at the shoulder (flexion) (Pearson correlation coefficient 
rp = -.601; Spearman correlation coefficient rs = -.607), elbow (rp = -.436; rs = -.495) and wrist (rp 
= -.206; rs = -.305) joints, as well as reduced muscle strength for elbow flexion (rp = -.547; rs = -
.618). The relationship between the MAS scores and the muscle strength for elbow extension 
was weak (rp = -.160; rs = -.191). Analysis between the FM-UE subscale and MAS revealed a 
significant negative correlation. The strongest correlation occurred between the FM-UE total 
score (rp = -0.817; rs = -0.806), while the weakest correlation amongst all subscales occurred 
between coordination subscale (rp = -0.696; rs = -0.684). A one-way, between-subjects design 
ANOVA showed significant mean differences between MAS scores and all FM-UE subscales: 
the FM-Arm subscale (F4,15 = 17.4, p < .001), the FM-Wrist subscale (F4,15 = 4.3, p < 0.016), the 
FM-Hand subscale (F4,15 = 4.8, p < 0.011), the FM-Corr subscale (F4,15 = 4.4, p < 0.015) as well 
as FM-Total Score subscale (F4,15 = 12.6, p < 0.001). Overall, there was a tendency for increased 
levels of spasticity per scoring of the MAS to result in decreased motor performance as measured 
by the FM-UE subscale. There was a moderate negative correlation between MAS score and the 
Stroke Index Scale hand subscale (rp = -0.543; rs = -0.576), indicating that a higher MAS score 
may be indicative of the magnitude of impairment in the hand. No significant relationships were 
demonstrated between the remaining subscales of the Stroke Impact Scale, suggesting that there 
is little to no relationship between MAS scores and overall health status. In comparing EMG 
activity and motion capture analysis, there was a marked increase in the EMG response when the 
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subjects affected limb is stretched into full elbow extension, such phenomenon was not observed 
when stretching the unaffected limb.  
Conclusion: The strong correlation between MAS scores and the residual impairments as 
well as the FM-UE subscale suggests that a higher MAS score may be indicative of the general 
stage of motor recovery following incurrence of a stroke. Additionally, there was a marked 
increase in EMG activity through passive stretching of the affected limb into full elbow 
extension; conversely, such a phenomenon was not observed in the unaffected limb. 
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I. Introduction 
Background 
 
Spasticity is a feature of altered skeletal muscle performance involving hypertonia, and 
has been described as one of the most debilitating complications of neurologic conditions in 
patients with stroke, brain injury, spinal cord injury, cerebral palsy, or multiple sclerosis. Cohort 
studies have revealed that 20-40% of stroke survivors are spastic (Leathley et al., 2004; 
Sommerfeld, Eek, Svensson, Holmqvist, & von Arbin, 2004; Watkins et al., 2002). Patients with 
spasticity may experience painful spasms, increased muscle stiffness, and loss of joint range of 
motion (Botte, Nickel, & Akeson, 1988; Ivanhoe, Francisco, McGuire, Subramanian, & 
Grissom, 2006; Kamper, Schmit, & Rymer, 2001). Severe spasticity may cause functional 
challenges in various aspects of daily living such as dressing, self-cares, and eating (Bhimani & 
Anderson, 2014; Jagatsinh, 2009; Katz & Rymer, 1989; Zorowitz, Gillard, & Brainin, 2013). 
Furthermore, prolonged spasticity that typically persists for 12 months or more after stroke may 
lead to postural deformity and contracture. The interaction between neural and biomechanical 
components of spasticity and its potential impact on functional limitation has been described by 
Barnes & Johnson (Figure 1).  
Modified Ashworth Scale 
 The Modified Ashworth Scale (MAS), modified from the Ashworth (AS) Scale, is the 
most commonly utilized clinical measure of quantifying spasticity (Table 1) (Ashworth, 1964; 
Bohannon & Smith, 1987). The original Ashworth Scale introduced in 1964 was constructed 
using a 5-point ordinal scale, with a Likert-like grade score of 0 (indicating no increase in muscle 
tone), 1, 2, 3, or 4 (affected part rigid in flexion or extension) to quantify spasticity. In 1987, 
Bohannon and Smith introduced the grade of “1+” and proposed slight changes in how each 
score was defined in order to increase the sensitivity of the measure and facilitate greater ease in 
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scoring, which prompted the renaming of the Ashworth Scale as the “Modified Ashworth Scale” 
(Bohannon & Smith, 1987). To evaluate elbow spasticity using the MAS, for example, the 
clinician quickly and passively stretches the patient’s affected elbow. The clinician would 
support the patient’s affected extremity at the elbow joint in 90 degrees of shoulder abduction 
while placing the other available hand on the volar aspect of the patient’s wrist to provide 
support. The clinician begins by bringing the patient’s elbow into maximum flexion, quickly 
stretching the elbow into maximum extension to assess flexor spasticity (i.e., stretching the 
biceps muscle), and finally moving the elbow back into the starting position of maximum elbow 
flexion to assess extensor spasticity (i.e., stretching the triceps muscle).  
The MAS, although simple to administer and convenient, has been criticized. Briefly, it is 
highly subjective to the clinician’s personal experience and the velocity at which the affected 
extremity is passively stretched. Some studies showed that the scale lacks inter-rater reliability 
(e.g., inter-rater reliability: mean = 0.56-0.76, agreement = 66%, 59-78%, intra-rater reliability = 
32%, 62-72%) (Blackburn, van Vliet, & Mockett, 2002; Fleuren et al., 2010; Gregson et al., 
1999; Gregson et al., 2000; Sloan, Sinclair, Thompson, Taylor, & Pentland, 1992). Studies have 
illustrated that the MAS also suffers from a clustering effect wherein most of the patients are 
grouped within the middle grades (Damiano et al., 2002). The MAS scores were not significantly 
associated with electromyography changes and only moderately associated with resistance. 
Ambiguity of wording and lack of standardized procedures limit the scale’s usefulness for 
comparison across studies. There are no clear guidelines for stretching velocity during 
administration of the MAS. It is possible that variable stretching velocities can affect the 
elicitation of spasticity. There is also poor scale sensitivity to change for rigorous clinical and 
research application. Overall, studies showed that reliability differs from muscle to muscle, and 
3 
suggested that assessment technique must be standardized and adequate training is required to 
ensure inter-rater reliability.  
Additional studies have challenged the scale’s validity, contending that it does not 
adequately distinguish between neurological and mechanical factors that contribute to joint 
stiffness (Kumar, Pandyan, & Sharma, 2006; Pandyan et al., 1999; Platz, Eickhof, Nuyens, & 
Vuadens, 2005). Furthermore, the MAS does not account for skeletal muscle changes, such as 
contractures, which are not necessarily attributable to spasticity alone (Foran, Steinman, Barash, 
Chambers, & Lieber, 2005).  
Numerous studies have explored the relationship between MAS scores and 
neurophysiological variables. In particular, a study led by Cooper et al. produced findings that 
indicated a positive correlation of MAS scores with magnitude and duration of surface 
electromyography response. The authors concluded that this finding is evidential that the MAS 
reflects spasticity in terms of surface electromyography response during passive stretch (Cooper, 
Musa, van Deursen, & Wiles, 2005). Similar studies have sought to corroborate this contention, 
but have only found moderate associations between MAS scores and electromyography, 
indicating that the scale may be more of a measure of hypertonia rather than spasticity (Bakheit, 
Maynard, Curnow, Hudson, & Kodapala, 2003; Lin & Sabbahi, 1999; Pisano et al., 2000; Skold, 
Harms-Ringdahl, Hultling, Levi, & Seiger, 1998). Instead, a more significant relationship was 
yielded in other studies that examined the relationship between MAS scores and objective 
measurements of resistance to passive movement, again elucidating what the MAS is actually 
constructed to measure. While utilization of descriptive measures such as the MAS continues, 
measures that provide the clinician with neurophysiological characteristics has been advocated. It 
is clear that discrepancies between clinical measures like the MAS and real neurophysiological 
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measures (i.e., surface electromyography) persist. Bridging this gap is critical to provision of 
appropriate anti-spasticity treatment.  
Current research trends suggest that there is a substantial effort underway to discover 
novel therapeutic technologies and strategies to treat spasticity (Bhakta, Cozens, Chamberlain, & 
Bamford, 2000; Brashear et al., 2002; Phadke, On, Kirazli, Ismail, & Boulias, 2013; Pittock et 
al., 2003; Remy-Neris, Tiffreau, Bouilland, & Bussel, 2003; Shakespeare, Boggild, & Young, 
2003). A host of clinical studies examining the effects of surgical, pharmacological, or 
therapeutic spasticity interventions refer to the MAS as an outcome measure (Bohannon & 
Smith, 1987). One particular study by Ivanhoe et al. examined the effects of intrathecal baclofen 
and produced positive results demonstrating a reduction in subjects’ spasticity per scoring of the 
MAS (Ivanhoe et al., 2006). However, an ordinal scale such as the MAS may lack sensitivity and 
precision for noting smaller degrees of change in spasticity, thus making it difficult to 
corroborate the study’s conclusions and subsequently limiting clinical application of its findings. 
Likewise, other studies examining the effect of surgical intervention in individuals with cerebral 
palsy have produced lower MAS scores (Butler & Campbell, 2000; McLaughlin et al., 1998), 
purporting that the surgical intervention was successful. The generalizability of these studies, and 
others alike, is inconspicuous due to the limitations of the MAS. Because the MAS is highly 
subjective to the clinician’s personal opinion, some researchers have contended that clinicians 
stop using the Ashworth Scale for the assessment of spasticity (Fleuren et al., 2010).  
Clinical Significance 
Stroke is the leading cause of disability in the adult population, affecting over 4 million 
people in the United States alone (Hinojosa, Rittman, & Hinojosa, 2009). More than one out of 
every four patients develops spasticity after experiencing a stroke (Wissel et al., 2010). As a 
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serious detriment to daily function and quality of life, proper management of spasticity is an 
important component of many rehabilitation protocols. Spasticity is a complex 
pathophysiological phenomenon, and, as such, should not rely on a subjective scale for 
quantification.  
Although reliability and validity of the MAS has been criticized, currently there is no 
clinical measurement that outperforms the MAS in quantifying spasticity (Blackburn et al., 2002; 
Gregson et al., 1999; Pandyan et al., 1999). One solution in advancing the spasticity measure is 
to improve the precision during administering the MAS by taking away the subjective factor 
(i.e., develop a quantitative spasticity device in routine clinical care). Increased objectivity in the 
quantification of spasticity has the potential to assist physicians and therapists in anti-spasticity 
management and more accurately illustrate the effects of interventions that have otherwise been 
deemed as ineffective or inconclusive.  
Specific Aims 
Before developing a quantitative spasticity device in routine clinical care, it is important 
to understand how the MAS scores translate into functional measures and quantitative kinematic 
and/or kinetic values. As the first step, we proposed to conduct a pilot study. Our specific aims 
are: 
1. To examine the relationships between the MAS and residual impairments (active range of 
motion of shoulder flexion, elbow, and wrist, and muscle strength of the elbow flexion 
and extension). 
2. To explore the relationships between the MAS and functional limitations as measured by 
Fugl-Meyer upper extremity assessment, finger to nose movement, and ability to grasp a 
bottle of water. 
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3. To investigate the relationship between the MAS and overall health status following 
stroke as measured by the Stroke Impact Scale.   
For aims 1 to 3: Data from 20 subjects (6 female, 14 male; mean age 57 ± 10) with chronic 
hemiparesis secondary to a cerebrovascular accident (stroke) will be used to examine the 
relationships. The data were collected at the Rehabilitation Institute of Chicago. 
4. To inspect whether there are potential kinematic values or physiological responses that 
can be used to identify the characteristics of the passive stretch (passive stretch duration, 
catch angle, electromyography response).  
For aim 4: A case study will be used to inspect the graphical presentation of the kinematics 
during passive stretching. The data were collected at the University of Wisconsin-Milwaukee. 
 
II. Literature Review  
Pathophysiology of Stroke 
Cerebrovascular accident (CVA), commonly known as simply stroke, is a neurological 
event characterized by an abrupt disruption in cerebral circulation producing an array of 
neurological deficits. While the neurological mechanisms of stroke are widely variable, stroke is 
delineated into two broad categories (ischemic stroke and hemorrhagic stroke) based on clinical 
manifestation of symptoms.  
Ischemic strokes occur when there is a disruption in blood flow in the brain for seconds 
or minutes, resulting in infarction (cell death). Infarction occurs if the brain is deprived of 
circulation for more than a few minutes. It could due to atherosclerosis, excess plaque buildup in 
the aortic arch, carotid arteries, or cerebral vessels, or emboli, traveling intravascular masses in 
the arteries. The most common precipitating event of cardioembolic strokes is occlusion of the 
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middle cerebral artery or the posterior cerebral artery in the brain. Unlike atherosclerotic events, 
symptoms that are produced from an embolus are often more sudden, producing severe, 
observable neurological deficits. Regardless of etiology, the clinical presentation in cerebral 
ischemic/infarction events is predicated upon the site of occlusion in the artery. Common clinical 
presentation of ischemic stroke includes but is not limited to weakness and loss of sensation in 
the contralateral leg and foot, contralateral sensory loss and weakness, loss of the nasal half of 
vision on the opposite side and loss of the temporal half of vision on the same side, aphasia, 
neglect, ataxia, vertigo, hiccupping, and difficulty swallowing (Frizzell, 2005).  
Hemorrhagic strokes are the third most common cause of stroke and are associated with 
about a 50% mortality rate. These occur when there is a leak or rupture in a vessel causing 
intracerebral bleeding, commonly in the basal ganglia, thalamus, pons, and cerebellum. The 
onset of hemorrhagic strokes can be both non-traumatic and traumatic in nature. Neurological 
deficits are dependent upon the site and severity of the hemorrhage and typically appear 
abruptly, developing over of a span of 30 to 90 minutes. The most severe deficits typically 
present within hours of onset, with gradual improve as edema subsides and extravascular blood 
is removed (Frizzell, 2005).  
Pathophysiology of Spasticity 
 Spasticity is a form of hypertonia, or excess muscle tone, classically defined by Lance 
(1980) as an increased resistance to a passive stretch. The increased resistance is a result of a 
velocity-dependent increase in tonic stretch reflexes that occurs from hyper-excitability of the 
stretch reflex, which is one component of the upper motor neuron syndrome (Lance, 1980). In a 
2001 interdisciplinary workshop sponsored by the National Institutes of Health, spasticity was 
defined as hypertonia with either one or both of the following present: (1) resistance to externally 
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imposed movement that increases with increasing speed of stretch and varies with the direction 
of joint movement or (2) resistance to externally imposed movement increases above a threshold 
speed or joint angle (Sanger et al., 2003). Other proposed mechanisms of spasticity include 
fusimotor neuron hyperactivity, hyperexcitable motor neurons, abnormal excitability of the 
spinal segmental and intersegmental interneurons from loss of supraspinal influences, as well as 
changes in the properties of the muscles themselves (Sehgal & McGuire, 1998). Newer research 
has refined this definition suggesting that spasticity is also a sensorimotor phenomenon with 
other alterations present in the central nervous system as part of the upper motor neuron 
syndrome (Ivanhoe & Reistetter, 2004). The velocity dependency in spasticity is a key 
distinguishing feature from other similar motor disorders in which there is changed resistance to 
passive movement at a joint, such as in the rigidity often present in people with Parkinson’s 
disease. Normally, in an unperturbed central nervous system, any resistance observed in the full 
range of joint movement should be solely due to biomechanical factors and electromyography 
activity would not be elicited. In spasticity, however, there is damage to the corticospinal tracts, 
which results in an increase of stretch reflexes that are normally latent.  
In essence, spasticity is manifested largely by overactive neural input to muscles, which 
causes excessive muscle contraction. This neural over-activity is a result of two underlying 
mechanisms: hyperreflexia and brainstem upper motor neuron over activity. In hyperreflexia, 
there is an absence of corticospinal inhibition onto lower motor neurons, which evokes a 
heightened reflexive response. The lack of corticospinal inhibition furthermore produces an 
excessive lower motor neuron response to muscle spindle input. Likewise, lesions that disinhibit 
the reticulospinal and/or vestibulospinal tracts result in brainstem overactivity (Ivanhoe & 
Reistetter, 2004). Spasticity becomes problematic when it interferes with postural alignment, 
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activities of daily living, sleep, or produces pain or discomfort (Lundy-Ekman, 2013). Clinically, 
spasticity has been delineated into both positive and negative symptoms. The conglomerate of 
positive and negative features of spasticity comprises the upper motor neuron syndrome. Positive 
aspects of spasticity include increased muscle tone, exaggerated stretch reflexes, positive 
Babinski sign, clonus, and flexor/extensor spasms. Negative features encompass loss of a 
particular functional capacity that is ordinarily controlled by the lesioned area of the brain, which 
include loss of strength, dexterity, and motor control (Biering-Sorensen, Nielsen, & Klinge, 
2006). The intricate pathophysiology of spasticity has obscured how clinicians define and 
identify spasticity in the clinical setting.  
 The primary objective in clinical treatment approaches for spasticity management is 
premised on modifying the degree of muscle imbalance through weakening the contractile 
effects of involuntary muscle over activity in a given pattern in order to prevent irreversible soft-
tissue changes and tendon contractures (e.g., flexor or extensor synergy). There are a range of 
both conservative treatments and interventional measures to achieve this, including occupational 
and physical therapies, oral and intrathecal medications, surgery, and focal chemical denervation 
with phenol, alcohol, and botulinum neurotoxin (BoNT).  
Brunnstrom Recovery Stages 
In 1970, Brunnstrom proposed sequential stages of motor recovery following stroke 
based on the degree of spasticity and voluntary movement. Each stage progression indicates less 
presence of spasticity and improved motor performance. Brunnstrom’s recovery stages are the 
only stroke-specific assessment in tracking the progression of motor recovery following stroke. 
Six stages of motor recovery have been described. In stage one, flaccidity is present and no 
movements of the limbs can be initiated. In stage two, the basic limb synergies or some of their 
components may appear as associated reactions or minimal voluntary movement responses may 
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be present and spasticity begins to develop. In stage three, the patient gains voluntary control of 
the movement synergies, although full range of all synergy components does not necessarily 
develop and spasticity is severe. In stage four, some movement combinations that do not follow 
the synergies are mastered and spasticity begins to decline. In stage five, more difficult 
movement combinations are possible as the basic limb synergies lose their dominance over 
motor acts. Finally, in stage six, individual joint movements become possible (Brunnstrom, 
1970). Brunnstrom’s stages of recovery have been widely utilized by clinicians, giving rise to a 
multitude of standardized assessments used by both occupational and physical therapists in the 
assessment of motor performance following the onset of stroke.  
 
III. Methods 
Study Design 
This was a prospective, cross-sectional research study in which all data was be collected 
during a single 2.5-hour experimental session. The Institutional Review Board at Northwestern 
University and the University of Wisconsin-Milwaukee approved the project. 
Subjects 
Stroke subjects were recruited from the Clinical Neuroscience Research Registry, a 
research database management system that is updated and maintained by clinicians at the 
Rehabilitation Institute of Chicago (RIC), and research flyers were distributed near the 
Milwaukee area.  
Eligibility for participation in the study included any history of stroke without regard to 
time elapsed from onset, upper extremity weakness or loss of function, as well as diagnosed 
spasticity in the elbow flexors and extensors in adults between the ages of 18-85. Exclusion 
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criteria included presence of orthopedic impairment of the shoulder, elbow, wrist, or hand joints; 
pain in any of the aforementioned musculoskeletal regions, or severe cognitive deficits that limit 
ability to follow simple commands.  
Clinical Assessment 
Before the motion caption data collection, each subject’s non-paretic and paretic arms 
was evaluated for clinical assessments including light touch sensation, isometric muscle strength, 
spasticity, motor function and overall health status following stroke.  
Light touch sensation was measured at 3 locations on the arm using the Semmes-
Weinstein monofilaments 5PC touch-test hand kit (2.83, 3.61, 4.31, 4.56, and 6.65) (Sammons 
Preston Rolyan, Germantown, WI) at the upper arm, forearm, and hand. Results from touch 
sensation were classified as intact if all sensation tests were normal; impaired if any of the tests 
indicated sensation loss; and absent if patients could not identify the largest monofilament at any 
of the testing locations.  
 Maximum isometric muscle strength was tested using the Lafayette hand-held muscle 
tester (Lafayette Instruments, Lafayette, IN) in 2 upper limb movements: elbow flexion and 
extension.  
Severity of spasticity was assessed using the modified Ashworth Scale (MAS) 
(Bohannon & Smith, 1987). Each subject’s elbow was quickly and passively stretched by an 
occupational therapist. Spasticity is manifested by a catch angle and resistance to passive stretch. 
The degree of spasticity was rated using ordinal response categories using a scale of 0 to 5, 
where “0” corresponds to no increase in muscle tone (no spasticity) and “5” indicating that the 
affected joint is highly rigid during flexion or extension (severe spasticity). 
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We evaluated the upper limb motor function using the Fugl-Meyer Assessment scale – 
upper extremity subscale (FM-UE) (Fugl-Meyer, Jaasko, Leyman, Olsson, & Steglind, 1975), a 
scale based on the theoretical framework of the Brunnstrom recovery scale describing the 
recovery phases following stroke and is widely used in both clinical and research settings. The 
FM-UE is composed of 33 tasks with a 3-point rating scale (0 to 2) that assesses reflex-activity 
(3 items), dynamic movement within flexor and extensor synergy patterns (15 items), wrist 
stability (5 items), hand function (7 items), and coordination (3 items). The score range of the 
FM-UE is from 0 to 66, with higher measures representing higher levels of functionality. The 
FM-UE subscale has excellent interrater reliability (r = 0.995-0.996) (Duncan, Propst, & Nelson, 
1983; Gladstone, Danells, & Black, 2002).  
The Stroke Impact Scale (SIS) was administered to subjects to evaluate how the stroke 
impacted the subject’s health and life. The SIS is a 59-item measure that assesses eight different 
domains: strength (4 items), hand function (5 items), ADL/IADL (10 items), mobility (9 items), 
communication (7 items), emotion (9 items), memory and thinking (7 items), and 
participation/role function (8 items). Each item is rated in a 5-point Likert scale in terms of 
difficulty the patient has experienced in completing each item. An additional question asking the 
patient to rate the recovery from their stroke on a scale of 0-100 is included at the end of the 
questionnaire. The questionnaire has established test-retest reliability, ranging from adequate to 
excellent (ICC = 0.70-0.92, except for the emotion domain, ICC = 0.57). Inter-rater reliability is 
reported as excellent for the hand function (ICC = 0.82) and mobility domains (ICC = 0.80), 
adequate for strength (ICC = 0.61), ADL/IADL (ICC = 0.64), and the memory and thinking (ICC 
= 0.43) domains, and poor for the communication (ICC = 0.39), emotion (ICC = 0.17), and 
13 
social participation (ICC = 0.29) domains (Carod-Artal, Ferreira Coral, Stieven Trizotto, & 
Menezes Moreira, 2009; Duncan et al., 1999).  
Experimental Setting  
The Vicon motion capture system (7 Vicon MCam2 Cameras with 1.3 Megapixels) was 
used to record the motion of reflective markers affixed to the upper arms and trunk. Subjects 
were instructed to sit on a stationary chair with neither back nor arm support. The predominant 
head axis of the global coordinate system, the Y axis, is defined as the forward facing direction 
(front-back). The secondary X axis is the lateral axis from right to left, orthogonal to the Y axis. 
The third Z axis follows the right-thumb rule, pointing up (vertical to the floor) and is orthogonal 
to both the X and Y axes. Kinematic data was recorded at a sampling rate of 120 Hz. 
Reflective Marker Placement 
The Vicon Plug-In-Gait upper body model (see Appendix 1) for each subject 
encompassed the trunk, upper extremities, and head, and was made using twenty-nine spherical 
reflective markers. The markers were attached to the body using double-sided adhesive tape. 
Bilaterally, markers will be placed on the acromion, inferior angle of the scapula, lateral 
humerus, lateral epicondyle of the humerus, forearm, wrist (radial and ulnar aspects), and the 
base of index finger. The trunk is defined at C7 of the cervical column, T10 of the thoracic spine, 
the jugular notch, the sternum, and the sacrum. The hips are bilaterally defined at the anterior 
superior and the posterior superior iliac spine. Markers defining the bilateral anterior and 
posterior head will be fixed to a head band that each subject will wear.  
Electromyography (EMG) Sensor Placement 
A total of four EMG sensors (Delsys, Natick, MA) were affixed with adhesive tape 
bilaterally to the muscle bellies of the biceps and triceps of both the affected and unaffected arm 
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to record muscle activity. EMG placement sites were cleaned with alcohol wipes to remove dead 
skin cells and maintain signal strength. These two sites were selected to assess the presence of 
flexor or extensor spasticity, specifically.  
Tasks during Motion Capture 
A standard protocol was administered to each subject, and both sides of the upper body 
were tested. The contralateral side (non-paretic) was precedent, and subjects were told to attempt 
to duplicate each task with the paretic arm.  
Active range of motion (AROM). The clinician instructed the subject to attempt to move 
the paretic arm into all arm planes of movement to assess AROM. Ranges at the shoulder joint 
(shoulder flexion), elbow joint (elbow flexion/extension), and wrist joint (wrist 
flexion/extension) were calculated. 
Passive stretch of the elbow. The clinical passive stretching test was performed by the 
same occupational therapist who initially evaluated the subjects’ spasticity. The catch angle (in 
degrees) was defined as the elbow position at which the therapist initially encountered resistance 
of the paretic arm. The kinematic data corroborated this position, for the position was also the 
point at which elbow angular velocity suddenly declined. The resistance to passive stretching 
was quantified by the stretch duration (in seconds) that the therapist needed to complete a single 
stretching test: from maximum elbow flexion to full extension (a test of flexor spasticity), and 
from full extension back to maximum flexion (a test of extensor spasticity). 
Finger-to-Nose (F-to-N) Reaching Task. Reaching is the most essential movement of 
upper limb function involving the shoulder and elbow. Reaching performance is critical since the 
arm needs to be placed in the desired position to support hand activities, such as grasping and 
manipulating objects. A rhythmic F-to-N reaching task was used to assess the overall arm 
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function. For this task, a height-adjustable target was positioned at the subject’s shoulder height, 
oriented at the center of the body, and at about 90% of the extended arm length. Subjects were 
instructed to touch the target with their index fingers and then touch their noses as many times as 
possible within a 30s period. One repetition of F-to-N is the movement from the nose to the 
target and then back to the nose. We define several variables of interest. The relative 
completeness of the reaching movement, which we will call the path ratio (PR), is the ratio of the 
paretic arm’s maximal reaching distance in the Y-axis from nose to target to that of the 
contralateral arm. Maximum path ratio will be set to 1. Efficiency of arm movement is as the 
total time needed to complete 5 repetitions of the F-to-N movement.  
Note that the experiment setup for the case study at University of Wisconsin-Milwaukee 
mirrored that of the experimental setup at the Rehabilitation Institute of Chicago except the 
following minor differences. The Vicon motion capture system (6 Vicon Bonita Cameras with 16 
Megapixels) was used to record the motion of reflective markers. In addition, the clinician placed 
and held a mini force sensor on the medial and lateral aspects of the subject’s wrists to collect the 
level the force exerted on the upper limb tested during administration of the passive stretch. 
Figure 2 shows the experimental setup, sensor placements, and beginning and end positions 
when performing the passive stretching during the motion capture at the University of 
Wisconsin-Milwaukee site.  
Analysis 
The motion-caption data was digitally low-pass filtered at 6Hz with a 4th-order finite-
impulse response filter to attenuate high-frequency noise without altering the signal phase. To 
examine the relationships between the MAS and selected variables, we first inspected the scatter 
plots (a) between the MAS and residual impairments (active range of motion of shoulder flexion, 
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elbow, and wrist, and muscle strength of the elbow flexion and extension), (b) between the MAS 
and functional limitations as measured by Fugl-Meyer upper extremity assessment, finger to 
nose movement, and ability to grasp a bottle of water, and (c) between the MAS and overall 
health status following stroke as measured by the Stroke Impact Scale. Pearson correlation 
coefficients and Spearman correlation coefficients were computed. One-way ANOVA will be 
used to compare the overall mean differences of the selected variables by MAS ratings. The 
significant level was set at 0.05. Post-hoc analysis will not be used as follow-up procedures due 
to small sample size per MAS ratings.  
To inspect whether there are potential kinematic values or physiological responses that 
can be used to identify the characteristics of the passive stretch (passive stretch duration, catch 
angle, electromyography response), a case study was used to compare the performance between 
affected arm and unaffected arm during passive stretch. For this thesis, Vicon data was processed 
following the Plug-In-Gait model within the Nexus software. The kinematic data was graphed 
with the elbow joint angle as a function of time. Both EMG data and force data are presented as 
raw data to inspect the differences between the affected arm and unaffected arm during passive 
stretch.  
 
IV. Results 
 Relationship between MAS and residual impairments. Figure 3 shows the scatterplot 
between MAS scores and residual impairments (active range of motion of shoulder, elbow and 
wrist, and muscle strength of elbow flexion and extension). Overall, results showed that stroke 
subjects who had more severe spasticity tended to have reduced range of motion at the shoulder 
(flexion) (Pearson correlation coefficient rp = -.601; Spearman correlation coefficient rs = -.607), 
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elbow (rp = -.436; rs = -.495) and wrist (rp = -.206; rs = -.305) joints, as well as reduced muscle 
strength for elbow flexion (rp = -.547; rs = -.618). The relationship between the MAS scores and 
the muscle strength for elbow extension was weak (rp = -.160; rs = -.191).   
 Relationship between MAS and functional limitations. Figure 4 summarizes the results of 
the relationship between the MAS scores and the FM-UE subscale. Analysis between the FM-UE 
subscale and MAS revealed a significant negative correlation. The strongest correlation occurred 
between the FM-UE total score (rp = -0.817; rs = -0.806), while the weakest correlation amongst 
all subscales occurred between coordination subscale (rp = -0.696; rs = -0.684). A one-way, 
between-subjects design ANOVA showed significant mean differences between MAS scores and 
all FM-UE subscales: the FM-Arm subscale (F4,15 = 17.4, p < .001), the FM-Wrist subscale (F4,15 
= 4.3, p < 0.016), the FM-Hand subscale (F4,15 = 4.8, p < 0.011), the FM-Corr subscale (F4,15 = 
4.4, p < 0.015) as well as FM-Total Score subscale (F4,15 = 12.6, p < 0.001). Overall, there was a 
tendency for increased levels of spasticity per scoring of the MAS to result in decreased motor 
performance as measured by the FM-UE subscale. 
 Relationship between MAS and overall health status. Figure 5 demonstrated the 
relationship between the MAS scores and overall health status per the Stroke Impact Scale 
subscales. There was a moderate negative correlation between MAS score and the hand subscale 
(rp = -0.543; rs = -0.576), indicating that a higher MAS score may be indicative of the magnitude 
of impairment in the hand. No significant relationships were demonstrated between the 
remaining subscales of the Stroke Impact Scale, suggesting that there is little to no relationship 
between MAS scores and overall health status.  
 Case Study. By inspecting the motion capture raw data, there was a marked increase in 
the EMG response when the subjects affected limb is stretched into full elbow extension (Figure 
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6, supplement with one Video clip), such phenomenon was not observed when stretching the un-
affected limb.  
 
V. Discussion 
 The strong correlation between MAS scores and the residual impairments as well as the 
FM-UE subscale suggests that a higher MAS score may be indicative of the general stage of 
motor recovery following incurrence of a stroke. However, the severity of spasticity may not 
predict an individual’s overall health status as measured using the Stroke Impact Scale.  
To the best of our knowledge, there is no previous literature explicitly examining the 
correlation between the MAS and the Fugl Meyer Assessment and Stroke Index Scale. However, 
previous studies have ascertained similar results regarding the MAS and residual upper extremity 
impairment (Denham, 2008). Previous studies have proposed that effectively operationalizing the 
definition of quality of life and overall health status could contribute to more objective 
measurement of the relationship between spasticity management and health status and quality of 
life (Gianino JM, York MM, Paice JA, et al., 1998). 
While results from this study were variable, it was evident that there were several 
significant correlations between MAS scores and functional impairments, as well as 
neurophysiological variables such as EMG through inspection of raw EMG data and the motion 
capture videos. One previous study, however, confounds these findings. Alibiglou et al. (2008) 
investigated the quantitative measures of spasticity and their relationship to the MAS 
demonstrated a lack of significant correlation between the MAS and quantitative measures of 
stroke including neural and muscular components (Alibiglou et al., 2008). In short, the study 
reported that the MAS does not provide reliable information about quantitative measures 
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associated with spasticity or about its contributing components. Because spasticity is an intricate 
neurophysiological phenomenon and the MAS does not have adequate objectivity in accurately 
quantifying clinical assessment of spasticity, it is clear that the inconspicuous results in this 
previous study and others alike are faced with an aggregate of challenges in validly and reliably 
quantifying spasticity.  
The results gleaned from the case study suggested that there is significance in the amount 
of spasticity present and the magnitude of EMG produced during passive stretching. Though we 
were unable to clearly examine the effect of velocity and force on the amount of produced 
resistance during passive stretching, it is likely that increased force and velocity is conducive to 
an increased tonic reflex (catch angle) and resistance force through passive stretching.  
Future directions of research to examine the MAS and functional impairments through 
using motion capture and EMG should increase the case study into case series by collecting 
stroke subjects within each MAS strata to more closely inspect these quantitative measures and 
produce more clear results.  
 
VI. Conclusions 
The strong correlation between MAS scores and the residual impairments as well as the 
FM-UE subscale suggests that a higher MAS score may be indicative of the general stage of 
motor recovery following incurrence of a stroke. Additionally, there was a marked increase in 
EMG activity through passive stretching of the affected limb into full elbow extension; 
conversely, such a phenomenon was not observed in the unaffected limb.  
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Limitations and Potential Contributions  
Because this particular study has no specificity in regard to the amount of time elapsed 
following the onset of stroke, it may be difficult to generalize the study’s findings to a large 
population because spasticity can evolve over the course of time. Because functional recovery 
following strokes typically occurs during the first three months following onset, it would be 
important to include a more heterogeneous group of participants for future studies. Stroke 
generally affects older adults, however, there has been a growing trend of younger people 
incurring stroke, and the sample size does not account for this emerging trend. Furthermore, the 
modest sample size further constrains the amount of generalizability. The use of two force 
sensors instead of one as well as increasing the amount of motion capture cameras to minimize 
the gaps in the data frames could also increase objectivity and fidelity. Utilizing an organic 
motion capture system and more motion capture cameras could additionally improve the findings 
from this study. Finally, incorporating an independent MAS clinical assessment evaluator (blind 
assessor) could improve the reliability of this study.  
This study has the potential to reduce the subjectivity of the MAS and translate it into 
functional values, a highly prominent clinical assessment for spasticity in stroke patients and 
other populations where spasticity is present such as individuals with stroke, multiple sclerosis, 
cerebral palsy, traumatic brain injury, or spinal cord injury. Reducing the subjectivity will yield 
an increased ability for the clinician to appropriately address spasticity treatment, track progress 
in treatment plans, and more clearly illustrate therapeutic outcomes. Additionally, accurate 
measurement of spasticity as a result eradication of subjective MAS components will enable 
clinical researchers to more easily illustrate efficacy of studies examining novel therapeutic or 
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pharmacological treatment strategies for persons with spasticity while using the MAS as an 
outcome measure. 
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TABLES/FIGURES 
 
Table 1. Ashworth Scale and Modified Ashworth Scale. 
Score Ashworth Scale (1964) Modified Ashworth Scale 
Bohannon & Smith (1987) 
0 (0) No increase in tone No increase in muscle tone 
1 (1) Slight increase in tone giving a 
catch when the limb was moved in 
flexion or extension 
Slight increase in muscle tone, manifested 
by a catch and release or by minimal 
resistance at the end of the range of 
motion when the affected part(s) is moved 
in flexion or extension 
1+ (2)  Slightly increase in muscle tone, 
manifested by a catch, followed by 
minimal resistance throughout the 
remainder (less than half) of the ROM 
(range of movement) 
2 (3) More marked increase in tone but 
limb easily flexed 
More marked increase in muscle tone 
through most of the ROM, but affected 
part(s) easily moved 
3 (4) Considerable increase in tone – 
passive movement difficult 
Considerable increase in muscle tone – 
passive movement difficult 
4 (5) Limb rigid in flexion or extension Affected part(s) rigid in flexion or 
extension 
Abbreviations: ROM=range of movement 
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Table 2. Subject demographics from Rehabilitation Institute of Chicago data collection sample (n 
= 20) 
 
 Min Max Mean SD 
Age (years) 27.0 70.0 57.4 10.3 
Time Since Onset of Stroke (months) 12.0 433.0 151.8 113.9 
Height (m) 1.60 1.93 1.73 8.9 
Weight (kg) 50.0 135.0 80.3 17.2 
BMI (kg/m^2)  18.8 36.0 26.7 4.3 
Abbreviations: SD = standard deviation; min = minimum; max = maximum; BMI = body mass 
index as calculated by the subject’s weight in kilograms (kg) divided by the square of height in 
meters (m).  
 
 
 
24 
Table 3. Relationship between MAS scores and residual impairments. 
  N Mean SD Pearson (rp) and 
Spearman's (rs) 
Correlation 
ANOVA 
Shoulder Flexion (º) 19 99.8 37.655 rp = -.601 
rs = -.607 
F4, 14 =  5.8 
p < 0.006 
Elbow Flexion (º) 19 53.7 16.223 rp = .436 
rs = .495 
F3, 15 = 1.4 
p < 0.287 
Wrist Flexion (º) 17 -44.0 28.131 rp = .206 
rs = .305 
F3, 13 = .427 
p < 0.737 
Elbow Flexion (kg) 19 7.6 5.178 rp = -.547 
rs = -.618 
F3, 15 = .3 
p < 0.844 
Elbow Extension (kg) 17 10.0 3.528 rp = -.160 
rs = -.191 
F3, 13 = .427 
p < 0.737 
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Table 4. Relationship between MAS and FM-UE subscales. 
  N Mean SD Pearson (rp) 
and 
Spearman's 
(rs) 
Correlation 
ANOVA 
FM-Arm 0 5 32.2 2.8636 rp =  -.815 
rs = -.829 
  
  
  
  
F4,15 = 17.4, p < .001 
  
  
  
  
  
1 5 26.6 6.6558 
2 1 5 . 
4 7 15 5.164 
5 2 5.5 3.5355 
Total 20 20.75 10.6468 
FM-Wrist 0 5 7 4.4721 rp = -.696 
rs = -.754 
  
  
  
  
F4,15 = 4.3, p < 0.016 
  
  
  
  
  
1 5 5.8 4.0866 
2 1 0 . 
4 7 0.571 1.5119 
5 2 0 0 
Total 20 3.4 4.26 
FM-Hand 0 5 9.8 4.7645 rp = -.714 
rs = -.728 
  
  
  
F4,15 = 4.8, p < 0.011 
  
  
  
  
1 5 8.2 4.3243 
2 1 1 . 
4 7 2.286 2.7516 
5 2 0.5 0.7071 
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Total 20 5.4 5.0409     
FM-Corr 0 5 3.8 2.2804 rp = -.696 
rs = -.684 
  
  
  
  
F4,15 = 4.4, p < 0.015 
  
  
  
  
  
1 5 3 1.8708 
2 1 0 . 
4 7 0.571 0.9759 
5 2 0 0 
Total 20 1.9 2.1497 
FM-Total 0 5 52.8 13.0652 rp = -.817 
rs = -.806 
  
  
  
  
F4,15 = 12.6, p < 0.001 
  
  
  
  
  
1 5 43.6 14.1174 
2 1 6 . 
4 7 18.429 7.5246 
5 2 6 2.8284 
Total 20 31.45 20.4874 
Abbreviations: FM-UE = Fugl-Meyer upper extremity; SD = standard deviation.  
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Table 5. Relationship between MAS scores and overall health status. 
  N Mean SD Pearson (rp) and 
Spearman's (rs) 
Correlation 
ANOVA 
Subscale 1 Strength 19 12.9 2.7501 rp = -.186 
rs = -.281 
F4,14 = 3.1, p < 0.053 
Subscale 2 Cognition 19 32.9 2.6893 rp = .007 
rs = .064 
F4,14 = 0.2, p < 0.925 
Subscale 3 Emotion 19 34.7 6.7521 rp = -.009 
rs = .073 
F4,14 = 0.5, p < 0.724 
Subscale 4 Speech 19 34.3 1.1471 rp = .081 
rs = .223 
F4,14 = 0.2, p < 0.944 
Subscale 5 ADL 19 40.8 5.7547 rp = .083 
rs = .114 
F4,14 = 0.4, p < 0.819 
Subscale 6 Walk 19 40.9 3.3177 rp = -.190 
rs = -.203 
F4,14 = 2.5, p < 0.094 
Subscale 7 Hand 19 12.7 6.7646 rp = -.543 
rs = -.576 
F4,14 = 2.4, p < 0.097 
Subscale 8 Social 19 34.1 5.227 rp = .170 
rs = .268 
F4,14 = 0.2, p < 0.939 
Total Score 19 2432.1 20.9858 rp = -.162  
rs = -.188 
F4,14 = 0.9, p < 0.506 
Abbreviations: SD = standard deviation. 
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Figure 1. A model of the interaction between neural and biomechanical components of 
hypertonia in the upper motoneuron syndrome (Barnes & Johnson, 2001) 
 
 
 
Dynamic 
§ Spasms 
§ Co-contraction 
§ Clonus 
§ Associated reaction 
§ Flexor withdrawal 
Static 
§ Spasticity 
§ Spastic dystonia 
Hypertonia + Reduced ROM 
Abnormal postures 
Impaired function 
Abnormal muscular 
contraction 
Upper motor neuron (UMN) lesion 
Immobilization at 
short muscle length 
Biomechanical changes 
§ Reduced compliance 
§ Contracture 
Weakness 
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Figure 2. Motion capture experimental set-up at the University of Wisconsin-Milwaukee 
Innovation Accelerator motion analysis laboratory 
 
Figure 2A. The beginning position of the MAS is displayed. The clinician supports the spastic 
upper extremity while passive stretching is initiated to assess for flexor/extensor spasticity. 2B. 
The clinician places the mini force sensor on the medial aspect of the wrist during passive 
stretching. 2C. Placement of reflection motion capture sensors at various anatomical landmarks 
of the upper extremity. 2D. Placement of the electromyography sensor on the triceps. An 
electromyography sensor will also be placed on the muscle belly of the biceps.  
 
 
   
 
 
A B 
D 
Mini force sensor 
Electromyography 
sensor 
C 
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Figure 3. Relationship between Modified Ashworth Scale and residual impairments (active range 
of motion of shoulder flexion, elbow, and wrist, and muscle strength of elbow flexion and 
extension). 
 
Abbreviations: AROM = active range of motion; MAS = Modified Ashworth Scale. 
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Figure 4. Relationship between MAS and functional limitations as measured by Fugl-Myer upper 
extremity assessment, finger to nose movement, and ability to grasp a bottle of water.  
  
Abbreviations: FM = Fugl-Meyer upper extremity assessment subscale; MAS = Modified 
Ashworth Scale; F-to-N = finger-to-nose.  
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Figure 5. Relationship between MAS and overall health status following stroke as measured by 
the Stroke Impact Scale subscales.  
 
Abbreviations: SIS = Stroke Impact Scale (the SIS is a 59-item measure with 8 different domains 
wherein each subject rated each item on a 5-point Likert scale in terms of the difficulty they 
experienced in completing each item; summative scores were generated for each domain with a 
range of 0-100 with a higher score indicating less difficulty); ADL = activities of daily living. 
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Appendix  
Plug-in-Gait Marker Placement 
Head Markers 
LFHD Left front head Located approximately over the left temple 
RFHD Right front head Located approximately over the right temple 
LBHD Left back head Placed on the back of the head, roughly in a horizontal plane 
of the front head markers 
RBHD Right back head Placed on the back of the head, roughly in a horizontal plane 
of the front head markers 
Torso Markers 
C7 7th Cervical 
Vertebrae 
Spinous process of the 7th cervical vertebrae 
T10 10th Thoracic 
Vertebrae 
Spinous Process of the 10th thoracic vertebrae 
CLAV Clavicle Jugular Notch where the clavicles meet the sternum 
STRN Sternum Xiphoid process of the Sternum 
RBAK Right Back Placed in the middle of the right scapula. This marker has no 
symmetrical marker on the left side. This asymmetry helps 
the autolabeling routine determine right from left on the 
subject. 
Arm Markers 
LSHO Left shoulder 
marker 
Placed on the Acromio-clavicular joint 
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LUPA Left upper 
arm marker 
Placed on the upper arm between the elbow and shoulder 
markers. 
Should be placed asymmetrically with RUPA 
LELB Left elbow Placed on lateral epicondyle approximating elbow joint axis 
LFRA Left forearm 
marker 
Placed on the lower arm between the wrist and elbow 
markers. Should 
be placed asymmetrically with RFRA 
LWRA Left wrist 
marker A 
Left wrist bar thumb side 
LWRB Left wrist 
marker B 
Left wrist bar pinkie side 
LFIN Left fingers Actually placed on the dorsum of the hand just below the 
head of the 
second metacarpal 
Pelvis 
LASI Left ASIS Placed directly over the left anterior superior iliac spine 
RASI Right ASIS Placed directly over the right anterior superior iliac spine 
LPSI Left PSIS Placed directly over the left posterior superior iliac spine 
RPSI Right PSIS Placed directly over the right posterior superior iliac spine 
Leg 
Markers 
  
LKNE Left knee Placed on the lateral epicondyle of the left knee 
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LTHI Left thigh Place the marker over the lower lateral 1/3 surface of the 
thigh, just below the swing of the hand, although the height is 
not critical. 
LANK Left ankle Placed on the lateral malleolus along an imaginary line that 
passes through the transmalleolar axis 
LTIB Left tibial 
wand 
marker 
Similar to the thigh markers, these are placed over the lower 
1/3 of the shank to determine the alignment of the ankle 
flexion axis 
LTOE Left toe Placed over the second metatarsal head, on the mid-foot side 
of the equinus break between fore-foot and mid-foot 
LHEE Left heel Placed on the calcaneous at the same height above the plantar 
surface of the foot as the toe marker 
 
 
 
 
 
 
 
 
 
 
 
 
 
